EdwardFMcClayMD

Oncology • San Marcos, CA

Director, Melanoma Research

Join to view full profile

Dr. McClay is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. McClay's full profile

Already have an account?

Office
838 Nordahl Rd
Ste 300
San Marcos, CA 92069
Phone+1 760-747-8935

Fax+1 760-466-0078

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Hematology and Medical Oncology, 1984 - 1986
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 1981 - 1983
University of Arizona College of Medicine-Tucson (South Campus)Internship, Internal Medicine, 1980 - 1981
Lewis Katz School of Medicine at Temple UniversityClass of 1980

Certifications & Licensure

CA State Medical License 1988 - 2026
SC State Medical License 1993 - 1999
PA State Medical License 1981 - 1996
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Americas Top Doctors for Cancer Castle Conolly, 2012-2018
America's Top Doctors Castle Connolly, 2013-2014
Top Doctors:San Diego Area Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2012-2013
Top Doctors:Southern California Castle Connolly, 2012
Join now to see all

Clinical Trials

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma Start of enrollment: 2007 May 01
Unknown status
Phase 2
Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma Start of enrollment: 2007 Apr 01
Unknown status
Phase 2
Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas Start of enrollment: 2006 Dec 01
Unknown status
Phase 2
Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma Start of enrollment: 2007 May 01
Unknown status
Phase 1, Phase 2
Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma Start of enrollment: 2014 Mar 01
Unknown status
Phase 2
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2019 Apr 02
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

3 citations
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma.
Garni Barkhoudarian, Michael Badruddoja, Nicholas Blondin, Sajeel Chowdhary, Charles Cobbs
CNS Oncology. 2023-09-01
92 citations
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Julius Strauss, Margaret E. Gatti-Mays, Byoung Chul Cho, Andrew G. Hill, Sébastien Salas
Journal for Immunotherapy of Cancer. 2020-12-01
18 citations
Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study.
Claire F. Verschraegen, Guy Jerusalem, Edward F. McClay, Nicholas Iannotti, Charles H. Redfern
Journal for Immunotherapy of Cancer. 2020-09-01